Article
Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions.
Expert review of hematology - 1 Dec 2024
Troussard Xavier
Abstract excerpt
INTRODUCTION: Hairy cell leukemia accounts for less than 2% of leukemias. The hairy cells express CD11c, CD25, CD103, and CD123 markers. The BRAFV600E mutation was detected in 95% of HCL cases. Patients achieve high complete response rate with purine analogues with or without rituximab, but relapses are inevitable. HCL-like disorders including HCL variant, splenic diffuse red pulp lymphoma, and splenic marginal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
